niacinamide has been researched along with Dysmyelopoietic Syndromes in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation." | 5.15 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011) |
| "Sorafenib is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)." | 2.78 | A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. ( Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W, 2013) |
| "Sorafenib is a small molecule inhibitor of RAF kinase, VEGFR-2, c-KIT, and FLT3." | 2.75 | A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. ( Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R, 2010) |
| "We previously reported a flow cytometry technique to monitor pharmacodynamic effects of the raf kinase inhibitor BAY 43-9006 based on the ability of phorbol ester (PMA) to phosphorylate extracellular-regulated kinase (ERK) in peripheral blood (Chow et al." | 2.72 | Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. ( Chow, S; Hedley, D; Tong, FK, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tadmor, T | 1 |
| Tallman, MS | 1 |
| Polliack, A | 1 |
| Crump, M | 1 |
| Hedley, D | 2 |
| Kamel-Reid, S | 2 |
| Leber, B | 2 |
| Wells, R | 1 |
| Brandwein, J | 2 |
| Buckstein, R | 1 |
| Kassis, J | 1 |
| Minden, M | 1 |
| Matthews, J | 1 |
| Robinson, S | 1 |
| Turner, R | 1 |
| McIntosh, L | 1 |
| Eisenhauer, E | 1 |
| Seymour, L | 1 |
| Borthakur, G | 1 |
| Kantarjian, H | 1 |
| Ravandi, F | 1 |
| Zhang, W | 1 |
| Konopleva, M | 1 |
| Wright, JJ | 1 |
| Faderl, S | 1 |
| Verstovsek, S | 1 |
| Mathews, S | 1 |
| Andreeff, M | 1 |
| Cortes, JE | 1 |
| Liesveld, JL | 1 |
| Rosell, KE | 1 |
| Bechelli, J | 1 |
| Lu, C | 1 |
| Messina, P | 1 |
| Mulford, D | 1 |
| Ifthikharuddin, JJ | 1 |
| Jordan, CT | 1 |
| Phillips Ii, GL | 1 |
| Wei, A | 1 |
| Tan, P | 1 |
| Macdonald, DA | 1 |
| Assouline, SE | 1 |
| Eisenhauer, EA | 1 |
| Couban, S | 1 |
| Caplan, S | 1 |
| Foo, A | 1 |
| Walsh, W | 1 |
| Tong, FK | 1 |
| Chow, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646] | Phase 1 | 36 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Phase II Pilot Study of VELCADE in Patients With MDS[NCT00262873] | Phase 2 | 8 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy[NCT01869114] | Phase 2 | 57 participants (Actual) | Interventional | 2013-07-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00262873)
Timeframe: For 21 days/course for up to 12 courses
| Intervention | participants (Number) |
|---|---|
| Bortezomib | 6 |
Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14
| Intervention | number of colonies per 50000 cell plated (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 16.1 | 28.6 |
Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14
| Intervention | number of colonies per 50000 cell plated (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 14.75 | 14.75 |
Colony forming unit-granulocyte-macrophage (CFU-GM) progenitors, erythroid burst forming units (BFU-E), and leukemia colony forming units (CFU-L) were measured at day 0 and day 14 of cycle 1. Five × 10(4) light density cell for granulocyte-macrophage colony forming unit (CFU-GM) or erythroid burst forming unit (BFU-E) assays were plated in 0.9% methylcellulose, 30% FCS, 2 mmol/L L-glutamine, 10-4 mol/L β-mercaptoethanol, and 1% BSA with 3U/ml human erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, and 50 ng/ml stem cell factor (SCF) (c-kit ligand). For leukemia colony forming units (CFU-Ls), the plating mixture was comparable with the exception that the cytokines utilized were 4 U/ml erythropoietin, 10 ng/ml GM-CSF, 10 ng/ml IL-3, 100 ng/ml c-kit ligand, and 100 ng/ml Flt3 ligand. The methylcellulose mixture and associated reagents were purchased from Stem Cell Technologies (Vancouver, BC). Colonies were scored at Day 14 and were defined as > 20 grouped cells. (NCT00262873)
Timeframe: day 14
| Intervention | number of colonies per 50000 cell plated (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 27.65 | 54.28 |
The CD34+ fraction of light density marrow obtained from patients at baseline and while receiving bortezomib were assessed through measurement of Annexin V (assay obtained form R&D Systems) and by flow cytometry analysis. (NCT00262873)
Timeframe: day 14
| Intervention | percentage of apoptotic cells (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 6.68 | 11.37 |
"interleukin-6 levels were measured by enzyme-linked immunosorbant assay ELISA in serum from participants exposed to bortezomib.~Levels were measured at Day 0 and Day 14 of cycle 1 of the clinical trial." (NCT00262873)
Timeframe: day 14
| Intervention | pg/ml (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 6.8 | 8.6 |
VEGF levels were measured by ELISA (R&DSystems) in serum from participants exposed to bortezomib. Levels were measured at Day 0 and Day 14 of cycle 1 of the clinical trial. (NCT00262873)
Timeframe: day 14
| Intervention | pg/ml (Mean) | |
|---|---|---|
| pre bortezomib | post bortezomib | |
| Bortezomib | 402 | 254 |
5 trials available for niacinamide and Dysmyelopoietic Syndromes
2 other studies available for niacinamide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Sorafenib - a small molecule with big promise?
Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relation | 2010 |
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Niacinamide; Phenylurea C | 2013 |